Jose L. Coelho-Passos

Lisbon, Portugal

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 26 publications

Thromboembolic disease in testicular germ cell tumors-real-world evidence of three Portuguese institutions.

Thromboembolic disease in testicular germ cell tumors-real-world evidence of three Portuguese institutions.

Journal: Frontiers in oncology
Published: December 21, 2025

Unveiling the traits of HER2-low breast cancer: a comparative analysis of IHC1+ vs IHC2+/ISH-negative subgroups - insights from a 3-year cohort study.

Unveiling the traits of HER2-low breast cancer: a comparative analysis of IHC1+ vs IHC2+/ISH-negative subgroups - insights from a 3-year cohort study.

Journal: Frontiers in oncology
Published: July 28, 2025

The Use and Impact on Treatment Decision of the 21-Gene Recurrence Score Assay for Patients With HR+/HER2- Early Breast Cancer in Portugal: A Nationwide Retrospective Cohort Study.

The Use and Impact on Treatment Decision of the 21-Gene Recurrence Score Assay for Patients With HR+/HER2- Early Breast Cancer in Portugal: A Nationwide Retrospective Cohort Study.

Journal: Clinical breast cancer
Published: July 21, 2025

An Implementation Roadmap to Accelerate Academic Clinical Cancer Research in Portugal: A Multistakeholder Perspective.

An Implementation Roadmap to Accelerate Academic Clinical Cancer Research in Portugal: A Multistakeholder Perspective.

Journal: Acta medica portuguesa
Published: June 03, 2025

Real-Life Experience of HER2 (Human Epidermal Growth Factor Receptor 2)-Positive Advanced Breast Cancer Patients Treated With T-DXd (Trastuzumab Deruxtecan): A Multicentric Portuguese Study.

Real-Life Experience of HER2 (Human Epidermal Growth Factor Receptor 2)-Positive Advanced Breast Cancer Patients Treated With T-DXd (Trastuzumab Deruxtecan): A Multicentric Portuguese Study.

Journal: Cureus
Published: February 26, 2025

Study design for DESTINY-Breast Respond HER2-low Europe: T-DXd in patients with HER2-low advanced breast cancer.

Study design for DESTINY-Breast Respond HER2-low Europe: T-DXd in patients with HER2-low advanced breast cancer.

Journal: Future oncology (London, England)
Published: April 09, 2024

Case report: Treatment with Phesgo® in a patient receiving hemodialysis.

Case report: Treatment with Phesgo® in a patient receiving hemodialysis.

Journal: Frontiers in oncology
Published: December 02, 2023

A Rare Case of Isolated Prostate Recurrence From Testicular Seminoma.

A Rare Case of Isolated Prostate Recurrence From Testicular Seminoma.

Journal: Cureus
Published: November 06, 2023

Loss of RAS Mutations in Liquid Biopsies of Patients With Multi-Treated Metastatic Colorectal Cancer.

Loss of RAS Mutations in Liquid Biopsies of Patients With Multi-Treated Metastatic Colorectal Cancer.

Journal: The oncologist
Published: July 17, 2023

SARS-CoV-2 Antibody Seroprevalence in Patients With Cancer on Systemic Antineoplastic Treatment in the First Wave of the COVID-19 Pandemic in Portugal.

SARS-CoV-2 Antibody Seroprevalence in Patients With Cancer on Systemic Antineoplastic Treatment in the First Wave of the COVID-19 Pandemic in Portugal.

Journal: Cureus
Published: February 21, 2022

Lymph node yield in the pathological staging of resected nonmetastatic colon cancer: The more the better?

Lymph node yield in the pathological staging of resected nonmetastatic colon cancer: The more the better?

Journal: Surgical oncology
Published: January 21, 2022

Functional Mapping of AKT Signaling and Biomarkers of Response from the FAIRLANE Trial of Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast Cancer.

Functional Mapping of AKT Signaling and Biomarkers of Response from the FAIRLANE Trial of Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: July 15, 2021
Showing 1-12 of 26

Last Updated: 09/26/2026